Suppr超能文献

碱基切除修复缺陷引发对PARP抑制的超敏反应。

Base excision repair defects invoke hypersensitivity to PARP inhibition.

作者信息

Horton Julie K, Stefanick Donna F, Prasad Rajendra, Gassman Natalie R, Kedar Padmini S, Wilson Samuel H

机构信息

Laboratory of Structural Biology, NIEHS, NIH, Research Triangle Park, North Carolina.

Laboratory of Structural Biology, NIEHS, NIH, Research Triangle Park, North Carolina

出版信息

Mol Cancer Res. 2014 Aug;12(8):1128-39. doi: 10.1158/1541-7786.MCR-13-0502. Epub 2014 Apr 25.

Abstract

UNLABELLED

PARP-1 is important for the recognition of both endogenous and exogenous DNA damage, and binds to DNA strand breaks including intermediates of base excision repair (BER). Once DNA-bound, PARP-1 becomes catalytically activated synthesizing PAR polymers onto itself and other repair factors (PARylation). As a result, BER repair proteins such as XRCC1 and DNA polymerase β (pol β) are more efficiently and rapidly recruited to sites of DNA damage. In the presence of an inhibitor of PARP activity (PARPi), PARP-1 binds to sites of DNA damage, but PARylation is prevented. BER enzyme recruitment is hindered, but binding of PARP-1 to DNA is stabilized, impeding DNA repair and leading to double-strand DNA breaks (DSB). Deficiencies in pol β(-/-) and Xrcc1(-/-) cells resulted in hypersensitivity to the PARP inhibitor 4-AN and reexpression of pol β or XRCC1, in these contexts, reversed the 4-AN hypersensitivity phenotype. BER deficiencies also showed evidence of replication defects that lead to DSB-induced apoptosis upon PARPi treatment. Finally, the clinically relevant PARP inhibitors olaparib and veliparib also exhibited hypersensitivity in both pol β(-/-) and Xrcc1(-/-) BER-deficient cells. These results reveal heightened sensitivity to PARPi as a function of BER deficiency.

IMPLICATIONS

BER deficiency represents a new therapeutic opportunity to enhance PARPi efficacy.

摘要

未标记

聚(ADP - 核糖)聚合酶1(PARP - 1)对于识别内源性和外源性DNA损伤很重要,并且能与DNA链断裂处结合,包括碱基切除修复(BER)的中间体。一旦与DNA结合,PARP - 1就会被催化激活,在自身和其他修复因子上合成聚(ADP - 核糖)聚合物(PARylation)。结果,诸如X射线修复交叉互补蛋白1(XRCC1)和DNA聚合酶β(polβ)等BER修复蛋白能更高效、快速地被招募到DNA损伤位点。在存在PARP活性抑制剂(PARPi)的情况下,PARP - 1会与DNA损伤位点结合,但PARylation被阻止。BER酶的招募受到阻碍,但PARP - 1与DNA的结合得以稳定,从而阻碍DNA修复并导致双链DNA断裂(DSB)。在polβ( - / - )和Xrcc1( - / - 细胞中存在缺陷会导致对PARP抑制剂4 - 氨基烟酰胺(4 - AN)超敏,而在这些情况下,polβ或XRCC1的重新表达会逆转4 - AN超敏表型。BER缺陷还显示出复制缺陷的证据,这些缺陷在PARPi处理后会导致DSB诱导的细胞凋亡。最后,具有临床相关性的PARP抑制剂奥拉帕利和维利帕利在polβ( - / - )和Xrcc1( - / - )BER缺陷细胞中也表现出超敏性。这些结果揭示了对PARPi的敏感性增强是BER缺陷的一种表现。

启示

BER缺陷代表了增强PARPi疗效的新治疗机会。

相似文献

1
Base excision repair defects invoke hypersensitivity to PARP inhibition.
Mol Cancer Res. 2014 Aug;12(8):1128-39. doi: 10.1158/1541-7786.MCR-13-0502. Epub 2014 Apr 25.
2
Preventing oxidation of cellular XRCC1 affects PARP-mediated DNA damage responses.
DNA Repair (Amst). 2013 Sep;12(9):774-85. doi: 10.1016/j.dnarep.2013.06.004. Epub 2013 Jul 18.
3
DNA polymerase β-dependent cell survival independent of XRCC1 expression.
DNA Repair (Amst). 2015 Feb;26:23-9. doi: 10.1016/j.dnarep.2014.11.008. Epub 2014 Dec 3.
4
XRCC1 prevents toxic PARP1 trapping during DNA base excision repair.
Mol Cell. 2021 Jul 15;81(14):3018-3030.e5. doi: 10.1016/j.molcel.2021.05.009. Epub 2021 Jun 7.
5
Temporal recruitment of base excision DNA repair factors in living cells in response to different micro-irradiation DNA damage protocols.
DNA Repair (Amst). 2023 Jun;126:103486. doi: 10.1016/j.dnarep.2023.103486. Epub 2023 Mar 22.
7
8
The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2'-deoxycytidine lesions.
Nucleic Acids Res. 2014 Aug;42(14):9108-20. doi: 10.1093/nar/gku638. Epub 2014 Jul 29.

引用本文的文献

2
PARP inhibitor response is enhanced in prostate cancer when XRCC1 expression is reduced.
NAR Cancer. 2025 Apr 23;7(2):zcaf015. doi: 10.1093/narcan/zcaf015. eCollection 2025 Jun.
3
Overview of Wnt/β-Catenin Pathway and DNA Damage/Repair in Cancer.
Biology (Basel). 2025 Feb 11;14(2):185. doi: 10.3390/biology14020185.
6
Harnessing the effects of hypoxia-like inhibition on homology-directed DNA repair.
Semin Cancer Biol. 2024 Jan;98:11-18. doi: 10.1016/j.semcancer.2023.11.007. Epub 2023 Nov 28.
7
Temporal recruitment of base excision DNA repair factors in living cells in response to different micro-irradiation DNA damage protocols.
DNA Repair (Amst). 2023 Jun;126:103486. doi: 10.1016/j.dnarep.2023.103486. Epub 2023 Mar 22.
8
The potential of PARP inhibitors in targeted cancer therapy and immunotherapy.
Front Mol Biosci. 2022 Dec 1;9:1073797. doi: 10.3389/fmolb.2022.1073797. eCollection 2022.
10
Roles of DNA damage repair and precise targeted therapy in renal cancer (Review).
Oncol Rep. 2022 Dec;48(6). doi: 10.3892/or.2022.8428. Epub 2022 Oct 20.

本文引用的文献

1
Suicidal cross-linking of PARP-1 to AP site intermediates in cells undergoing base excision repair.
Nucleic Acids Res. 2014 Jun;42(10):6337-51. doi: 10.1093/nar/gku288. Epub 2014 Apr 25.
2
Preventing oxidation of cellular XRCC1 affects PARP-mediated DNA damage responses.
DNA Repair (Amst). 2013 Sep;12(9):774-85. doi: 10.1016/j.dnarep.2013.06.004. Epub 2013 Jul 18.
3
Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.
Mol Cancer Ther. 2013 Jun;12(6):1002-15. doi: 10.1158/1535-7163.MCT-12-0813. Epub 2013 May 31.
4
PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks.
DNA Repair (Amst). 2013 Jul;12(7):529-34. doi: 10.1016/j.dnarep.2013.04.004. Epub 2013 May 16.
5
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.
Ann Oncol. 2013 May;24(5):1416-8. doi: 10.1093/annonc/mdt074. Epub 2013 Mar 22.
6
Targeting XRCC1 deficiency in breast cancer for personalized therapy.
Cancer Res. 2013 Mar 1;73(5):1621-34. doi: 10.1158/0008-5472.CAN-12-2929. Epub 2012 Dec 19.
7
Predicting enhanced cell killing through PARP inhibition.
Mol Cancer Res. 2013 Jan;11(1):13-8. doi: 10.1158/1541-7786.MCR-12-0512. Epub 2012 Nov 27.
8
Hyperactivation of PARP triggers nonhomologous end-joining in repair-deficient mouse fibroblasts.
PLoS One. 2012;7(11):e49301. doi: 10.1371/journal.pone.0049301. Epub 2012 Nov 7.
9
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
Cancer Res. 2012 Nov 1;72(21):5588-99. doi: 10.1158/0008-5472.CAN-12-2753.
10
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Cell Cycle. 2012 Oct 15;11(20):3837-50. doi: 10.4161/cc.22026. Epub 2012 Sep 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验